• Novartis received a positive CHMP opinion for Cosentyx in adolescents aged 12 and older with moderate to severe hidradenitis suppurativa.
• The recommendation covers patients with active disease who responded inadequately to conventional systemic therapy.
• A European Commission decision is expected within approximately two months; approval would make Cosentyx Europe's only IL-17A inhibitor for adolescent HS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611131330OMX_____CNEWS_EN_GNW1001303558_en) on November 13, 2026, and is solely responsible for the information contained therein.